172 related articles for article (PubMed ID: 38413217)
21. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
Wong H; Yau T
Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
[TBL] [Abstract][Full Text] [Related]
23. Advances of Molecular Targeted Therapy in Gastric Cancer.
Cetin B; Gumusay O; Cengiz M; Ozet A
J Gastrointest Cancer; 2016 Jun; 47(2):125-34. PubMed ID: 26875080
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
Aoki M; Iwasa S; Boku N
Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
[TBL] [Abstract][Full Text] [Related]
25. Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Bilici A
World J Gastroenterol; 2014 Apr; 20(14):3905-15. PubMed ID: 24744580
[TBL] [Abstract][Full Text] [Related]
26. Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.
Narita Y; Muro K
Expert Opin Drug Saf; 2017 Mar; 16(3):319-327. PubMed ID: 27976952
[TBL] [Abstract][Full Text] [Related]
27. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
28. Targeting HER 2 and angiogenesis in gastric cancer.
Jomrich G; Schoppmann SF
Expert Rev Anticancer Ther; 2016; 16(1):111-22. PubMed ID: 26567753
[TBL] [Abstract][Full Text] [Related]
29. Recent advances and future trends in the targeted therapy of metastatic gastric cancer.
Al-Batran SE; Werner D
Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):555-69. PubMed ID: 24665840
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
Ciliberto D; Staropoli N; Caglioti F; Gualtieri S; Fiorillo L; Chiellino S; De Angelis AM; Mendicino F; Botta C; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2015; 16(8):1148-59. PubMed ID: 26061272
[TBL] [Abstract][Full Text] [Related]
31. Second-line chemotherapy for patients with advanced gastric cancer.
Takahari D
Gastric Cancer; 2017 May; 20(3):395-406. PubMed ID: 28260227
[TBL] [Abstract][Full Text] [Related]
32. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Roviello G; Aprile G; D'Angelo A; Iannone LF; Roviello F; Polom K; Mini E; Catalano M
Gastric Cancer; 2021 Jul; 24(4):765-779. PubMed ID: 33742317
[TBL] [Abstract][Full Text] [Related]
33. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
Pietrantonio F; Caporale M; Morano F; Scartozzi M; Gloghini A; De Vita F; Giommoni E; Fornaro L; Aprile G; Melisi D; Berenato R; Mennitto A; Volpi CC; Laterza MM; Pusceddu V; Antonuzzo L; Vasile E; Ongaro E; Simionato F; de Braud F; Torri V; Di Bartolomeo M
Int J Cancer; 2016 Dec; 139(12):2859-2864. PubMed ID: 27578417
[TBL] [Abstract][Full Text] [Related]
34. Hopes and failures in front-line advanced HER2-positive gastric cancer therapy.
Kong F; Yao Y; Deng R; Li X; Jia Y
Anticancer Drugs; 2021 Aug; 32(7):675-680. PubMed ID: 33929993
[TBL] [Abstract][Full Text] [Related]
35. Targeting receptor tyrosine kinases in gastric cancer.
Morishita A; Gong J; Masaki T
World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
[TBL] [Abstract][Full Text] [Related]
36. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
Kim CG; Jung M; Kim HS; Lee CK; Jeung HC; Koo DH; Bae WK; Zang DY; Kim BJ; Kim H; Yun UJ; Che J; Park S; Kim TS; Kwon WS; Park J; Cho SW; Nam CM; Chung HC; Rha SY
J Clin Oncol; 2023 Sep; 41(27):4394-4405. PubMed ID: 37364218
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.
Wang HB; Liao XF; Zhang J
Medicine (Baltimore); 2017 Nov; 96(44):e8437. PubMed ID: 29095284
[TBL] [Abstract][Full Text] [Related]
39. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
Tehfe M; Tabchi S; Laterza MM; De Vita F
Future Oncol; 2018 Feb; 14(3):223-228. PubMed ID: 29318901
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer.
Wang Y; Zhao C; Chang L; Jia R; Liu R; Zhang Y; Gao X; Li J; Chen R; Xia X; Bulbul A; Husain H; Guan Y; Yi X; Xu J
EBioMedicine; 2019 May; 43():261-269. PubMed ID: 31031019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
